Rofecoxib's Mechanism on Prostaglandins
Rofecoxib, a selective COX-2 inhibitor, blocks cyclooxygenase-2 (COX-2), the enzyme that produces prostaglandins involved in inflammation and pain. Unlike non-selective NSAIDs (e.g., ibuprofen), it spares COX-1, which generates gastroprotective prostaglandins like PGE2 and PGI2 in the stomach lining.[1]
How COX-1 Prostaglandins Protect the Stomach
Stomach prostaglandins from COX-1 maintain mucosal integrity by:
- Stimulating bicarbonate and mucus secretion to form a protective barrier against acid and pepsin.
- Promoting blood flow to support epithelial repair and nutrient delivery.
- Inhibiting acid secretion from parietal cells.
Non-selective NSAIDs inhibit COX-1, reducing these prostaglandins and causing ulcers, erosions, and bleeding in 15-30% of chronic users.[2]
Why Rofecoxib Reduces Stomach Risk
By selectively targeting COX-2 (induced during inflammation), rofecoxib preserves COX-1 activity and stomach prostaglandin levels. Clinical trials (e.g., VIGOR) showed it caused 50% fewer gastrointestinal ulcers and perforations compared to naproxen, with upper GI event rates of 0.8% vs. 1.6% over 9 months.[3][4]
Clinical Evidence and Limitations
Endoscopic studies confirmed rofecoxib's mucosal sparing: after 12 weeks, gastroduodenal ulcer incidence was 5.2% vs. 17.1% for ibuprofen.[5] However, risk isn't zero—long-term use still elevates events slightly above placebo (1.3% vs. 0.7%), especially in high-risk patients (e.g., elderly, H. pylori-positive).[6] Rofecoxib (Vioxx) was withdrawn in 2004 for cardiovascular risks, not GI issues.
Comparison to Other COX-2 Inhibitors
| Drug | GI Ulcer Risk Reduction vs. NSAIDs | Key Trials |
|------|------------------------------------|------------|
| Rofecoxib | ~50-70% | VIGOR, APPROVe [3][4] |
| Celecoxib | ~40-60% | CLASS [7] |
| Diclofenac + PPI | ~70-80% (comparable) | CONDOR [8] |
Sources
[1]: Nature Reviews Drug Discovery - COX Inhibition
[2]: Gastroenterology - NSAID Gastropathy
[3]: NEJM - VIGOR Trial
[4]: Lancet - Rofecoxib GI Safety
[5]: JAMA - Endoscopic Study
[6]: Aliment Pharmacol Ther - Long-term GI Risk
[7]: JAMA - CLASS Trial
[8]: Lancet - CONDOR